Helping to realize data-driven, personalized care that treats patients based on their unique genomic characteristics across therapeutic areas.
Our comprehensive survey of 1800 people in the US
Health and Life Sciences Experience Survey 2021READ MORE
We are rapidly moving towards individualized treatments and disease interventions that will change how we care for people around the world.
For years, patients diagnosed with a disease often received the same treatment. And for some people, that treatment worked. However, for others, it did not at all work – or only marginally or with serious side effects. This meant that, on average, only 50% of patients benefited from their treatment. With the mapping of the genome in combination with new, analytical scientific and technological advances, we can now develop personalized treatments for individuals or patient populations.
Huge advances in areas like cell and gene therapy, specifically in oncology and rare diseases are changing the treatment landscape. We conducted research to understand the key trends in precision oncology and how leaders are responding.
It’s our privilege to be working with the most progressive life sciences companies to bring precision medicine to people around the world.
Doctors treating cancer patients need excellent data to be comfortable with the decisions they make. The value is not bound up in the data itself but rather in the insights generated from large, combined datasets which help to predict patient outcomes and reduce the burden that cancer places on societies and health systems. High quality patient datasets are the foundation to bring precision oncology into clinical practice. To test the status quo, identify barriers to adoption and help unlock precision oncology’s full value, we surveyed 130 oncologists from the US and Europe.
Oncologists told us how they can benefit from sharing data, what kind of data they need and what will make the data truly useful for them. As a result of our research we created four essential steps necessary to capture the full potential of precision oncology.
Precision medicine holds great promise for reshaping the way we treat cancer, yet research shows that there are hurdles before realizing its full potential.
$2M
For the most expensive precision medicine today.1
700
New cancer drugs are currently in late-stage development, and over 90% of these are targeted therapies.2
67%
Increase in the number of active agents in the global immuno-oncology pipeline.3
1 Financial Times, 2019
2 The IQVIA Institute, 2018
3 Cancer Research Institute, 2019
We bring capabilities from early research through full commercialization in combination with deep technology and digital expertise to help our clients deliver personalized healthcare to their patients.
Bringing our deep precision medicine expertise to help clients design and build drug development for shifting manufacturing and commercial operations.
Shaping and designing industry-leading patient and healthcare professional experiences and services with our business service design arm Fjord.
Leveraging our data science expertise: accelerate R&D, enable clinically relevant biomarkers, action patient care analytics along their lifespan.
Aggregating, analyzing and actioning patient data and insight from across their healthcare and everyday experience using architectures and platforms, including INTIENT.
Cell and Gene Therapy (CGT) is growing in the fight against cancer and other diseases. We help our clients address the patient, product and value chain for CGT which requires new and specialized sets of capabilities.
3
Working with clients in all three commercially approved CGT therapies.
13
Active clients in CGT globally.
3
We are helping clients across three areas: R&D, supply chain and patient engagement.
The Cancer Patient Issue takes a human-centered approach—this time to uncover the main pain points for cancer patients.
A differentiated engagement is about understanding the needs of oncologists to better support them and doing so offers significant value to biopharma.
As New Science grows in prominence, a new economic environment is demanding change for biopharma’s.
Accenture helped a biopharma company implement a patient-centered platform to manage the delivery of a personalized gene therapy solution.
With data integration provided by Accenture, Roche's NAVIFY® Tumor Board is changing the way tumor board meetings are organized and conducted.
A biopharmaceutical company collaborates with Accenture to navigate a complex FDA submission for an innovative cell therapy.
Development and commercialization of cell and gene therapy requires embracing a shift in the traditional biopharmaceutical business model.
First in a two-part series on overcoming challenges in cell and gene therapy.
Second in a two-part series on overcoming challenges in cell and gene therapy.
This approach aims to enable pediatric oncology physicians and researchers to better analyze patient data, with the potential to improve precision medicine.
Life Sciences consultants weigh in on how pharma, biotech, medtech and consumer health companies can improve patient outcomes.
Accenture's Ted Boyle explores how healthcare industries can put the care back in healthcare.
Kingston Smith explores four pillars critical for biopharma companies to become truly data-driven enterprises.
filter result
Managing Director – Life Sciences, Precision Oncology and PHC, Global
1. Are New Science and Precision Medicine linked?
New Science and Precision Medicine are closely linked. New Science is a dynamic combination of the best in science and health technology that is projected to drive 61 percent of biopharma revenues until 2026, representing 81% of anticipated industry revenue growth. Precision Medicine has grown with the mapping of the genome to drive the development of personalized treatments for individuals or patient populations. Both work in combination with new, analytical scientific and technological advances to positively impact the biopharma business and help deliver better health outcomes. Discoveries are being made and tested in the cloud. Artificial intelligence and machine learning algorithms are digesting data lakes and helping drive new discoveries, speed development and provide smarter care. Accelerated development in cell and gene therapies (CGT) is causing a fundamental shift in the traditional biopharmaceutical business model. Both represent a medical revolution.
2. Why is oncology emphasized over other TAs?
New Science is driving exceptional growth across multiple therapeutic areas, but primarily in oncology. The one-size-fits-all cancer treatment approach has been replaced by personalized precision medicine. Standard cancer therapies are ineffective in over 75% of patients. One of the highest therapy failure rates for all diseases. Precision oncology is designed to change that.
3. What is cell and gene therapy used for?
One of the most exciting areas of innovation in medicine today is in the Cell and Gene Therapy (CGT) sector, with many therapies already changing the industry and patients’ lives. CGT is increasingly being viewed as a superior therapy for life-threatening illnesses such as cancer—and in a growing number of indications, it is being used as a first-line therapeutic approach with the potential to cure diseases entirely. While the science that supports CGT is complex, in the simplest of terms, CGT treats the underlying causes of disease by modifying an individual’s cells and/or genes, typically externally, and re-introducing them to the patient to treat the disease.
4. Does INTIENT support cell and gene therapy?
As demand for cell and gene therapies increases so does the demand for clinical trials. Industry leaders are focused on technology innovations, but struggle to find a holistic solution. While off-the-shelf digital solutions exist, they are typically focused on fragments of the overall process. As a result, they resort to the creation of bespoke solutions that create redundancies in the system. INTIENT Unify Cell & Gene connects stakeholders across the value chain, enabling manufacturers, supply chain partners and Healthcare Providers (HCPs) to work in a harmonized, standardized way.
